MUNTEANU, R.; MOLDOVAN, C.; TIGU, A.; DRULA, R.; FEDER, R.; MAGDO, L.; JURJ, A.; RADULY, L.; BUDISAN, L.; PIRLOG, R.; MOLDOVAN, A.; ZIMTA, A.; BRAICU, C.; PREDA, A.; MUNTEANU, V.; ROMITAN, M.; GULEI, D.; CIULEANU, T. 5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity. Medicine and Pharmacy Reports, v. 97, n. 4, p. 488-506, 23 set. 2024.